Drug Discovery 2017

Posters

Meera Raja
Sygnature Discovery
1A phenotypic screen to identify novel neuroprotective agents
Eve Rogers
University of Liverpool
2Effects of the Physico-Mechanical Environment and Circadian Timing on Adult Stem Cell Differentiation
Stephan Heyse
Genedata AG
Switzerland
3A Deep Learning Workflow for Quickly Establishing and Performing Image Analysis in Phenotypic Assays
Frederique Tholozan
ReproCELL
4Novel Hepatotoxic 3D Assay Model using HepG2 cells in a High-Throughput Alvetex 96-well Plate format
gary allenby
Aurelia Bioscience
5Protein-Protein interactions in Living Cells: Development of an assay to modulate Schnurri-3-ERK-2 using the Promega NanoBRET technology
Adam Zweifach
University of Connecticut
United States
6A novel ensemble approach to providing small molecule support for validation of cellular targets confirms that glycolysis is a viable antiproliferative strategy in leukemic cells.
Wouter Strijker
MIMETAS B.V.
Netherlands
7High-Throughput Microfluidic Platform for Culture of 3D-Kidney Tissue Models
Omar Rahman
GlaxoSmithKline
8The Application of Chemical Space Networks to Identify the Tracking and Retrospective pairing of Lead Compounds with Screening Hits.
Sarantis Chlamydas
Active Motif
Belgium
9Validation of Epigenetic Therapeutic Target Proteins for Homogenous Assay Performance
Claire Tebbutt
Domainex Ltd
10An Important role for TBK1/IKKε in IP10 signalling: A potential intervention in COPD
Bernice Wright
Imperial College London
11Development of Ferritin Nanocages as Drug Delivery Vectors
Shaheda Ahmed
Alcyomics Ltd
12Predicting adverse immune reactions to biopharmaceuticals using a human in-vitro skin explant test: a promising tool for biopharmaceutical R&D development
Tom Fleming
University of Oxford
13Modular, Fully-Automated HTS Assay & Hit Identification for a DNA Repair Nuclease
Oliver Wehmeier
acCELLerate
Germany
14Patch Ready Cells of CiPA Ion Channel Panel Cell Lines
Katherine Roper
Manchester Institute of Biotechnology
15Automating Glucose and Ethanol Measurement for Study of Diauxic Shift as a Model of the Warburg Effect
Celeste Letellier
AVACTA Life Sciences
16Isolation of Affimer® therapeutics with nanomolar affinity to human PD-L1 from a synthetic, phage display library
Teresa Valero
University of Bradford
17Assessment of drug promiscuity in cellulo through a nanotechnology approach
Carol De Santis
Newcastle University
18Evaluation of in-vitro cellular models for use in functional and structural studies of drug-induced cardiotoxicity
David Collins
Aptamer Group
19Aptamers as therapeutic delivery vehicles
Bryan Miller
Sygnature Discovery
20Live cell and high content imaging approaches identify apoptosis inducers in cell models of triple negative breast cancer
Oliver Wehmeier
acCELLerate
Germany
21Cryopreserved HepG2 Cells Used Instantly for Various Applications
Gerrit Erdmann
NMI TT Pharmaservices
Germany
22Signal transduction profiling and resistance marker identification in primary ovarian cancer
Gerrit Erdmann
NMI TT Pharmaservices
Germany
23Towards truly personalized medicines: Phenotypic, genetic and phosphoprotein profiling in patient-derived 3D tumor organoids (PD3Ds)
Alasdair Robertson
SAL Scientific Ltd
24Development of a novel 3D microfluidic assay platform for the assessment of human stem-cell derived epithelial function.
Derek Barratt
AstraZeneca
25Developing Kinases Assays on the Acoustic Mass Spectrometry Platform
Siobhán Leonard
LifeArc
26Anaplastic Lymphoma Kinase as an ADC target in neuroblastoma.
Siobhan Leonard
LifeArc
27Anaplastic Lymphoma Kinase as an ADC target in neuroblastoma.
Kate Simpson
Domainex
28Fragment screening against the lysine methyltransferase G9a using Microscale Thermophoresis
Claire McWhirter
AstraZeneca
29A New Poster AUse of AssayQuant Fluorogenic Peptides to Determine the Mechanism of Compound Inhibition and Potency for a Range of Tyrosine and Serine/Threonine Kinases. bstract
Amanda Benjamin
AstraZeneca
30The AstraZeneca Pharmaron Model of DMPK Screening: An Alliance Management Success Story
Vassilios Bavetsias
The Institute of Cancer Research, London
31Pyrido[3,4-d]pyrimidin-4(3H)-one C8-derivatisation: The identification of potent and cell penetrant dual KDM4/KDM5 histone lysine demethylase inhibitors
Ana J Narvaez
AstraZeneca
32Multiparametric and temporal characterisation of DNA-PK inhibitors to understand PK-PD-efficacy relationships and candidate drug selection
Alison Obergrussberger
Nanion Technologies GmbH
Germany
33Newest Advances in Automated Patch Clamp: Combining flexibility with high throughput
Gareth Davies
Astrazeneca
34An Evaluation of the Impact of Differential Scanning Fluorimetry as a Technique in High Throughput Screening
Alison Obergrussberger
Nanion Technologies GmbH
Germany
35Investigations into Idiosyncratic Drug-Induced Hepatotoxicity and Chronic Proliferation of Cancer Cells Using a Label-Free Method
Laurence Arnold
LifeArc, The Accelerator
36Targeting the translation initiation factor eIF4A1 with small molecules
Victoria Baskerville
LifeArc, The Accelerator
37Targeting the RNA helicase eIF4A1 with fragments
Alison Obergrussberger
Nanion Technologies GmbH
Germany
38Targeting Transporters with HTS Electrophysiology on the SURFE2R 96SE.
Devin Donnelly
Labcyte
United States
39Utilizing the Labcyte Echo® Liquid Handler to Validate the Generation of Recombinant Cell Lines by Next-Generation Sequencing
Devin Donnelly
Labcyte
United States
40A Miniaturized and Automated P450-Glo™ Screening System Using the Echo® Liquid Handler (with Promega Corp.)
Devin Donnelly
Labcyte
United States
41Detection of Phospho-Akt (Ser 473) as an Indication of PI3K Pathway Activation in MCF7 Cells Using the Labcyte Echo® Liquid Handler and Cisbio’s HTRF® Cellular Assay Kit
Devin Donnelly
Labcyte
United States
42Identification of PI3Ka Inhibitors with and Automated Echelon® Fluorescence Polarization Assay Using the Labcyte Access Workstation
Marie Fisher
Sygnature Discovery
43Predicting drug induced phospholipidosis using high resolution imaging in 2D and 3D cultures
Vaclav Navratil
IOCB AS CR
Czech Republic
44DIANA: A novel tool for ultra-sensitive enzyme detection and ultra-efficient screening of enzyme inhibitors
Bethany Nancolas
Charles River Discovery
45Comparison of branched DNA and qPCR assays for the quality control of stem cell differentiation
Tatiana Matviyuk
Enamine Ltd
Ukraine
46Discovery of novel chemistry-based approach for 19F NMR fragment screening against BRD4
Tatiana Matviyuk
Enamine Ltd
Ukraine
47Novel highly specific covalent warheads for Fragment library Synthesis: Functionalized Diazirines and New Amino Boronic Acids
Rasel Al-Amin
Uppsala University
Sweden
48Target Engagement-mediated Amplification: Selective Monitoring of Drug-Target Interactions
Simon Lydford
Molecular Devices (UK) Ltd
49Cardiotoxicity and Neurotoxicity Assessment Of Environmental Chemicals Using In Vitro Organotypic Human Induced Pluripotent Stem Cell-Derived Models
Matthew Mcloughlin
Scientist.com
50Scientist.com Introduces COMPLI™: A new standard in Human Biological Sample Acquisition
Phillip DeLand
Labcyte
United States
51Acoustic Mist Ionization for Ultra High Throughput Mass Spectrometry
Terry Riss
Promega Corporation
United States
52Real-Time Homogeneous Assay for Apoptosis using Complementation of Annexin V Luciferase Fragments
Juliet Morgan
Sygnature Discovery Ltd
53The use of complementary biophysical approaches to assess fragment binding to the epigenetic target bromodomain-containing protein 3 (BRD3)
Anthony Holmes
NC3Rs
54CRACK IT - An open innovation model for supporting improved drug development and animal welfare.
Anna Popova
Karlsruhe Institute of Technology
Germany
55Droplet-Microarray platform for cell-based high throughput compound screenings in nanoliter format
Steven van Helden
Pivot Park Screening Centre
Netherlands
56Statistics of HTS in the European Lead Factory: 4 Years of Screening for Public Partners
Lucas Kraft
Sussex Drug Discovery Centre
57Identification of novel ApoE4 modulators
Helena Lindmark
AstraZeneca Molndal
Sweden
58A Comparative Study of fluorescent assay technologies for a BET family Bromodomain target, BRD4(1).
Gemma Gothard
LifeArc
59Design and validation of a dual reporter assay to identify inhibitors of SOD1 transcription for the treatment of Amyotrophic Lateral Sclerosis
Alessandra Rossi
MedImmune
60Establishment of in vitro models of insulin resistance
Miniver Oliver
Essen Bioscience
6196-well live-cell assays for immune cell killing of 3D tumour spheroids
Hinnah Campwala
Essen BioScience
62Validation of IncuCyte® live-cell labelling dyes for monitoring immune and tumour cell interactions
Dan Leggate
Storm Therapeutics Ltd
63Using High Resolution Mass Spectrometry to characterise RNA modifications
Sam Jackson
NC3Rs
64The use of human tissue to improve translational research in drug discovery
Iaroslava Kos
ENAMINE Ltd.
Ukraine
65Differential Scanning Fluorimetry Provides High Throughput Data on Novel SIRT1 Inhibitors
Delyan Ivanov
AstraZeneca
66High-content screen to identify Drug Induced Liver Injury in monolayer HepG2 (C3A) cells
Puneet Khurana
AstraZeneca
67Developing high throughput biochemical kinetic assays using FLIPR Tetra® system
Asma Mohamed
Durham University
68Preclinical Determination of the Cardiotoxic Potential Associated with Vascular Disrupting Anticancer Therapies
Claire Hatty
NanoTemper Technologies, Ltd.
69Improved Biologics Workflow Utilizing a Single, Automated Platform to Effectively Monitor Protein Stability
Natsuko Macabuag
Charles River Discovery
70Screening and validating the HDAC PROTACs for Huntington’s disease treatment
George Cherian Pandarakalam
European Screening Centre, University of Dundee
71The use of biophysical techniques in selecting hit compounds from High Throughput Screening (HTS) at the European Lead Factory
Anders Hanning
Episentum AB
Sweden
72Label-Enhanced SPR for Improved Surface Plasmon Resonance Analysis of Small Molecules and Biomolecules
Sophie Foggin
AstraZeneca
73An Evaluation of the Impact of Differential Scanning Fluorimetry as a Technique in High Throughput Screening
Wolfgang Schlattl
S.A.F.AN. BIOINFORMATICS
Italy
74Drug Discovery of the next Calcilytics
Frank Craig
Sphere Fluidics Limited
75Cyto-Mine® an integrated platform for rapid therapeutic discovery from single cells.
Jenny Cook
LifeArc, The Accelerator
76Pharmacological and genetic validation of PAICS, a novel therapeutic target for cancer
David Chisholm
Durham University
77Fluorescent retinoids for cell biology and beyond
Joseph Shaw
AstraZeneca
78High throughput CETSA to determine intracellular binding and affinity of Androgen Receptor antagonists
Joanne Walter
EuroScitech
80MaxCyte Scalable Electroporation: A Universal Cell Engineering Platform for Development of Cell-based Medicines from R&D to Clinic
Katherine Carr
Avacta
81Crystal Structure of an Affimer® Biotherapeutic bound to human PD-L1 Target Antigen
Thomas Christott
Structural Genomics Consortium
82Developing selective inhibitors for the human YEATS domains
Vasiliki Paraskevopoulou
University of Nottingham
83Approaching stomach-targeted drug delivery by mimicking the mechanism of Helicobacter pylori
Joshua Burns
NCIMB Ltd & The Robert Gordon University
85Novel Streptomyces compound discovery by LC/MS guided screening of growth conditions
Victoria Day
BMG LABTECH Ltd
86Genetically encoded biosensor monitors redox processes in yeast colonies in response to changing oxygen environments
Lauren Cracknell
LGC Group
87Development of Solute Carrier (SLC) Transporters Kidney Cell Models Using hTERT-immortalized Renal Proximal Tubule Epithelial Cells (RPTEC/TERT1)
Qiuyu Wang
manchester metropolitan university
88Anticancer activity of arabinoxylan on human gastric adenocarcinoma cells in vitro
Marc Botcherby
Shelford Scientific
89Magnetic-microcontact printing based ECM nano-patterning allows homogeneous control of cell growth and behaviour
Lauren Cracknell
LGC Group
90Characterization of hTERT-immortalized Prostate-derived Stromal and Epithelial Cells: an Authentic in vitro Model for Tumour Microenvironment Studies
Richard Somberg
Promega
United States
91Broad Kinome Profiling of Target Engagement and Residence Time in Living Cells Using NanoBRET
Daniel Tams
Censo Biotechnologies
92iPSC derived Microglia-like cells
Kara Herlihy
AstraZeneca
93Using Protein Biochemistry and Gene Editing to Enable Mechanistic Target Validation of NSD2
Lotta Räty
Miltenyi Biotec
Germany
94Workflow automation and parallelization improves the isolation and analysis of tumor infiltrating immune subpopulations
Dave Thomas
Sartorius Stedim Biotech
96Reducing the Burden on Cell Culture Services by Implementing a Turn-Key Automation System
Alex Abadie
Takara Bio Europe
France
98Efficient footprint-free gene editing of hiPS cells using CRISPR/Cas9
Aayush Sharma
Takara Bio Europe
France
99Efficient footprint-free gene editing of hiPS cells using CRISPR/Cas9
Rachel Shuker
DiscoverX
100Novel, Improved Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors
Simon Butterworth
Kirkstall Ltd
101The Need for Metabolically Competent In Vitro Cell Culture in Drug Discovery
Abir Alkhfaji
Manchester Metropolitan University
102Investigating the effects of new inhibitors of LOX and LOXL2 on clear cell renal cell carcinoma in vitro
halah hammadi
university f manchester
103Treatment of inflammation: Novel VRAC inhibitors of the NLRP3 inflammasome
Frederique Tholozan
ReproCELL
104Construction of 3D mucosal intestinal model to enhance the structure and function of epithelia.
Simon Plummer
MicroMatrices
105Case Study: Anti-tumour effects of Temozolomide in a Novel Human Brain Glioblastoma 3D organotypic model.
Tomas Kulhanek
STFC Daresbury Laboratory
106West-life Virtual Folder - components and tools for integrative structural biology
Brecht Hoedemaekers
ImmunXperts SA
Belgium
107In Vitro Functional Bioassays of Candidate Therapeutics in Immuno-Oncology
Jason Otterstrom
Idea Bio-Medical Ltd
Israel
108High-content imaging and screening with automated analysis made easy using the Hermes® imaging system from IDEA Bio-Medical
Abir Alkhfaji
Manchester Metropolitan University
109Investigating the Effects of New Lysyl Oxidase (LOX) and Lysyl Oxidase Like 2 (Loxl2) Inhibitors on Clear Cell Renal Cell Carcinoma Cells (ccRCC) in Vitro
Ikuro Suzuki
Tohoku Institute of Technology
Japan
110Pain responses of cultured human iPSC-derived sensory neurons using MEA system
Jyrki Sivula
Avacta
111Fc fusion Affimer® Biotherapeutic Targeting PD-L1 Inhibits Tumour Growth in Mouse
Robert Haas
University of Vienna
Austria
112Computational drug design with nature's assembly lines
Isabel M Caballero
Pelago Bioscience
Sweden
113Physiologically relevant target engagement using CETSA
Antonia Konczwald
Beckman Coulter GmbH
Germany
114Fully-Automated Cellular Analysis by Flow Cytometry
Antonella Ragnini-Wilson
University of Rome Tor Vergata
Italy
115A nanofiber-based co-culture system to study myelination by oligodendrocytes
Yousif Khalaf
Strathclyde Institute of Pharmacy and Biomedical S
117Poster title: Novel first-in-class selective IKKα inhibitors as anti-cancer drugs
Robert Haas
University of Vienna
Austria
119Computational drug design with nature's assembly lines
Ann Kramer
The Electrospinning Company
120DEVELOPMENT OF PERFUSION PROCESS FOR PLURIPOTENT CELLS IN ELECTROSPUN SCAFFOLD-BASED MINI-BIOREACTOR
InSphero Marketing
InSphero AG
Switzerland
121A Microphysiological System Built For 3D Microtissue Spheroids
ATHEER AL-ZURFI
The University of Manchester
122The effects of NSAIDs on amyloid β1-42 peptide aggregation
Ya-Wen Hsiao
STFC Daresbury Laboratory
123AMP-membrane interaction characterized with atomistic MD simulation: a study on Cecropin B
David Jones
LifeArc
125A novel inhibitor of PAICS, an enzyme in the de novo purine synthetic pathway, exhibits selectivity and elicits cell cycle arrest resulting in a reduction in tumour growth
Kathy Dodgson
Aurelia Bioscience Ltd
126Utilisation of NanoBiT Luciferase (Promega) to examine Autophagy: Validation against other technologies
Mark Stephens
Beckman Coulter GmbH
Germany
127Fully-Automated Cellular Analysis by Flow Cytometry
Aisling Minard
University of Leeds
128Understanding the mode-of-action of TRPC4/5 ion channel inhibitors.
Ian Powley
University of Leicester
129Using an ex vivo Platform of Tumour Explants to Predict Clinical Response to Novel Anticancer Drugs
Emily Knight
Canterbury Christ Church University
130Identification of Cobra Venom Actives as Potential Novel Pancreatic Cancer Therapeutics
Michael Kelly
University of Leicester
131Applications of In-vivo Preclinical Imaging in Drug Discovery and Development
Hannah Williamson
University of Leeds
132Activating Challenging GPCR Targets with Venom Peptides
Ruediger Bader
Hamamatsu Photonics UK Ltd
133High-Throughput Fluorescence Measurements of Action Potential and Ca2+ Transients in Human iPSC-Derived Cells for Toxicity Screening and Drug Discovery
Gerrit Erdmann
NMI TT Pharmaservices
Germany
134iPSC-based Disease Models for Neurological Disorders and Individual 3D Tumour Co-Culture Models
Amanda Jones
PerkinElmer
135Distinguishing Cell Lines by Phenotypic Profiling of the Nucleus
Amanda Jones
PerkinElmer
136Setting up a 3D High Content Imaging Assay to study Cholestasis using the Opera Phenix High Content Screening System
Yousif Khalaf
Strathclyde Institute of Pharmacy and Biomedical Science
137Novel first-in-class selective IKKα inhibitors as anti-cancer drugs
Count: 130